Coronary arterial remodeling and out-stent plaque change after drug-eluting stent implantation - Comparison between zotarolimus-eluting stents and paclitaxel-eluting stents

Circulation Journal

Volumn 77, Issue 2, 2013, Pages 363-371

  Muraoka, Yoshitaka ^a   Sonoda, Shinjo ^a   Kashiyama, Kuninobu ^a   Kamezaki, Fumihiko ^a   Tsuda, Yuki ^a   Araki, Masaru ^a   Tamura, Masahito ^a   Takeuchi, Masaaki ^a   Abe, Haruhiko ^a   Okazaki, Masahiro ^a   Otsuji, Yutaka ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Drug eluting stent; Intravascular ultrasound; Out stent plaque; Paclitaxel eluting stent; Zotarolimuseluting stent

Indexed keywords

C REACTIVE PROTEIN; ENDEAVOR; PACLITAXEL; UNCLASSIFIED DRUG; ZOTAROLIMUS;

AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROTIC PLAQUE; CALCIFICATION; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CORONARY ARTERY; DRUG ELUTING STENT; EOSINOPHIL; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; INCIDENCE; INFLAMMATION; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EOSINOPHILS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RISK FACTORS; SIROLIMUS; TREATMENT OUTCOME; TUBULIN MODULATORS; ULTRASONOGRAPHY, INTERVENTIONAL; VASCULITIS; VENTRICULAR REMODELING;

EID: 84873850579     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0575     Document Type: Article

References (43)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
3. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.
4. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
5. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
6. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
7. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
8. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008; 118: 1138-1145.
9. Hao H, Ishibashi-Ueda H, Tsujimoto M, Ueda Y, Shite J, Gabbiani G, et al. Drug-eluting stent: Importance of clinico-pathological correlations. Circ J 2011; 75: 1548-1558.
10. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004; 109: 701-705.
11. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, et al. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175-181.
12. Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol 2011; 57: 390-398.
13. Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: A serial intravascular ultrasound analysis. J Am Coll Cardiol 2005; 46: 1002-1005.
14. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: Insights from the randomized TAXUS II trial. Circulation 2005; 111: 900-905.
15. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, et al. Late stent malapposition after drug-eluting stent implantation: An intravascular ultrasound analysis with long-term follow-up. Circulation 2006; 113: 414-419.
16. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115: 2426-2434.
17. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drugeluting stent thrombosis. Circulation 2009; 120: 391-399.
18. Hassan AK, Bergheanu SC, Stijnen T, van der Hoeven BL, Snoep JD, Plevier JW, et al. Late stent malapposition risk is higher after drugeluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2010; 31: 1172-1180.
19. Pinto Slottow TL, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the endeavor zotarolimus-eluting coronary stent. Circulation 2008; 117: 1603-1608.
20. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al. Comparison of zotarolimus-eluting and sirolimuseluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440-2447.
21. Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxeleluting stents for coronary revascularization: The ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimuseluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 2010; 56: 1187-1195.
22. Feres F, Andrade PB, Costa RA, de Ribamar Costa J Jr, Abizaid A, Staico R, et al. Angiographic and intravascular ultrasound findings following implantation of the Endeavor zotarolimus-eluting stents in patients from the real-world clinical practice. EuroIntervention 2009; 5: 355-362.
23. Sakurai R, Bonneau HN, Honda Y, Fitzgerald PJ. Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III. Am J Cardiol 2007; 100: 71M-76M.
24. Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III. Am Heart J 2008; 155: 108-113.
25. Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, et al. Intravascular ultrasound results from the ENDEAVOR IV trial: Randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv 2009; 2: 779-784.
26. Kawasaki M, Takatsu H, Noda T, Sano K, Ito Y, Hayakawa K, et al. In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings. Circulation 2002; 105: 2487-2492.
27. Okubo M, Kawasaki M, Ishihara Y, Takeyama U, Kubota T, Yamaki T, et al. Development of integrated backscatter intravascular ultrasound for tissue characterization of coronary plaques. Ultrasound Med Biol 2008; 34: 655-663.
28. Okubo M, Kawasaki M, Ishihara Y, Takeyama U, Yasuda S, Kubota T, et al. Tissue characterization of coronary plaques: Comparison of integrated backscatter intravascular ultrasound with virtual histology intravascular ultrasound. Circ J 2008; 72: 1631-1639.
29. Kawasaki M, Hattori A, Ishihara Y, Okubo M, Nishigaki K, Takemura G, et al. Tissue characterization of coronary plaques and assessment of thickness of fibrous cap using integrated backscatter intravascular ultrasound. Comparison with histology and optical coherence tomography. Circ J 2010; 74: 2641-2648.
30. Amano T, Matsubara T, Uetani T, Kato M, Kato B, Yoshida T, et al. Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: An integrated backscatter intravascular ultrasound study. Atherosclerosis 2011; 218: 110-116.
31. Ohota M, Kawasaki M, Ismail TF, Hattori K, Serruys PW, Ozaki Y. A histological and clinical comparison of new and conventional integrated backscatter intravascular ultrasound (IB-IVUS). Circ J 2012; 76: 1678-1686.
32. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: An intravascular ultrasound study. Circulation 2000; 101: 598-603.
33. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314-1322.
34. Higo T, Ueda Y, Oyabu J, Okada K, Nishio M, Hirata A, et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: An angioscopic study. JACC Cardiovasc Imaging 2009; 2: 616-624.
35. Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama K. Angioscopic evaluation of neointima coverage: Sirolimus drug-eluting stent versus bare metal stent. Am Heart J 2006; 152: 1168-1174.
36. Kim JS, Jang IK, Fan C, Kim TH, Park SM, Choi EY, et al. Evaluation in 3 months duration of neointimal coverage after zotarolimuseluting stent implantation by optical coherence tomography: The ENDEAVOR OCT trial. JACC Cardiovasc Interv 2009; 2: 1240 -1247.
37. Kim JS, Jang IK, Kim TH, Takano M, Kume T, Hur NW, et al. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: Comparison with sirolimus-eluting stents. Heart 2009; 95: 1907-1912.
38. Awata M, Nanto S, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Angioscopic comparison of neointimal coverage between zotarolimus- and sirolimus-eluting stents. J Am Coll Cardiol 2008; 52: 789-790.
39. Otagiri K, Tsutsui H, Kumazaki S, Miyashita Y, Aizawa K, Koshikawa M, et al. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: Analysis using integrated backscatter IVUS (ELAN study). Circ J 2011; 75: 633-641.
40. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112: 270-278.
41. Pires NM, Eefting D, de Vries MR, Quax PH, Jukema JW. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 2007; 93: 922-927.
42. Russo RJ, Silva PD, Teirstein PS, Attubato MJ, Davidson CJ, DeFranco AC, et al. A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial). Circ Cardiovasc Interv 2009; 2: 113-123.
43. Oonishi T, Hayabuchi Y, Sakata M, Mori K, Kagami S. Stent placement in the ductus venosus of a neonate with total anomalous pulmonary venous return. J Echocardiogr 2012; 10: 27-29.